Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
The NF-κB-inducing kinase (NIK), a molecule pivotal for immune system development and function, shows significant yet complex potential as a therapeutic target. The comprehensive review, published by ...
In people destined to get Alzheimer's in their mid-40s, one protein can delay the onset of the disease by about 20 years.
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Researchers identified a critical AMPK phosphorylation site that regulates mitochondria, muscle contraction, and sugar ...
A new experimental drug, Nerandomilast, has shown potential in reducing lung inflammation and fibrosis in preclinical models of Idiopathic Inflammatory Myopathy–Associated Interstitial Lung Disease ...
Explore how proteomics enables personalized medicine by improving patient stratification, treatment response, and diagnostics ...
Crystal jellyfish have an eerie beauty: thanks to a natural protein, they emit a faint green glow. For decades, researchers ...
The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.
The biological mystery of how many mammals transitioned from being nocturnal to active in the daytime following the extinction of the dinosaurs has been cracked by researchers in Cambridge. The study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results